Back to top
more

MannKind (MNKD)

(Real Time Quote from BATS)

$4.03 USD

4.03
1,410,691

+0.11 (2.81%)

Updated Aug 5, 2025 03:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 0% and 14.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Regenxbio (RGNX) delivered earnings and revenue surprises of -25.58% and 21.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -22.22% and 46.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

United Therapeutics (UTHR) Q4 Earnings & Sales Miss, Stock Down

by Zacks Equity Research

United Therapeutics (UTHR) fourth-quarter earnings and sales miss estimates. Higher sales of Tyvaso and Unituxin mainly drive the top line in the quarter, offset by lower sales of other drugs.

Zacks Equity Research

MannKind (MNKD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 20.00% and 8.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

United Therapeutics (UTHR) Q3 Earnings & Sales Beat, Stock Up

by Zacks Equity Research

United Therapeutics (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

Zacks Equity Research

Will MannKind (MNKD) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)

by Zacks Equity Research

United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

Zacks Equity Research

United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA

by Zacks Equity Research

United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

Zacks Equity Research

Do Options Traders Know Something About MannKind (MNKD) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.

Zacks Equity Research

MannKind (MNKD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of -25.00% and 31.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Stock Up

by Zacks Equity Research

United Therapeutics (UTHR) second-quarter earnings and sales beat estimates. Higher sales of Orenitram, Unituxin and Tyvaso mainly drive the top line in the quarter.

Zacks Equity Research

MannKind (MNKD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Company News for Jun 29, 2021

by Zacks Equity Research

Companies in the news are: NTLA, AVXL, MNKD, KYMR

Zacks Equity Research

United Therapeutics (UTHR) Tyvaso DPI Gets FDA's Priority Tag

by Zacks Equity Research

United Therapeutics' (UTHR) Tyvaso DPI is a drug device combination therapy, comprising the dry powder formulation of Tyvaso and a small, portable, dry powder inhaler.

Zacks Equity Research

Earnings Preview: MannKind (MNKD) Q1 Earnings Expected to Decline

by Zacks Equity Research

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

MannKind (MNKD) Looks Good: Stock Adds 5.6% in Session

by Zacks Equity Research

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Zacks Equity Research

MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of -25.00% and -2.48%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will MannKind (MNKD) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

MannKind (MNKD) in Focus: Stock Moves 8.7% Higher

by Zacks Equity Research

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Zacks Equity Research

MannKind (MNKD) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 0.00% and -0.52%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MannKind (MNKD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

MannKind (MNKD) Looks Good: Stock Adds 5.5% in Session

by Zacks Equity Research

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Zacks Equity Research

Implied Volatility Surging for MannKind (MNKD) Stock Options

by Zacks Equity Research

Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.

Zacks Equity Research

MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 50.00% and 7.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?